Back to top
more

Geron (GERN)

(Delayed Data from NSDQ)

$4.29 USD

4.29
37,963,996

+0.02 (0.47%)

Updated Nov 7, 2024 04:00 PM ET

After-Market: $4.27 -0.02 (-0.47%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (89 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Geron (GERN) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Geron (GERN) delivered earnings and revenue surprises of -12.50% and 82.67%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Geron (GERN) Begins Phase III Myelofibrosis Study on Imetelstat

by Zacks Equity Research

Geron (GERN) is evaluating its lead pipeline candidate, imetelstat, in late-stage studies for refractory myelofibrosis and myelodysplastic syndromes.

Geron (GERN) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

by Zacks Equity Research

Geron (GERN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Geron (GERN) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Geron (GERN) delivered earnings and revenue surprises of -20.00% and 44.00%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

What's in the Cards for Enlivex (ENLV) This Earnings Season?

by Zacks Equity Research

Investors will be keen on pipeline updates when Enlivex Therapeutics (ENLV) reports results for the three months ending Sep 30, 2020.

Is a Disappointment in Store for Tilray's (TLRY) Q3 Earnings?

by Zacks Equity Research

Investors will focus on revenue growth and other pipeline updates, when Tilray (TLRY) reports third-quarter 2020 results.

Qorvo, Nikola, BMY, MyoKardia and Geron as Zacks Bull and Bear of the Day

by Zacks Equity Research

Qorvo, Nikola, BMY, MyoKardia and Geron as Zacks Bull and Bear of the Day

Is a Disappointment in Store for Zosano (ZSAN) Q3 Earnings?

by Zacks Equity Research

Investors will be keen on updates on Qtrypta when Zosano (ZSAN) reports Q3 results.

Mylan (MYL) to Report Q3 Earnings: Is a Beat in the Cards?

by Zacks Equity Research

Investors will look forward to regular top and bottom-line numbers and updates on the merger with Upjohn, when Mylan (MYL) reports Q3 results.

Is a Beat in the Cards for Bristol-Myers' (BMY) Q3 Earnings?

by Zacks Equity Research

Investors will focus on regular top and bottom-line numbers along with key pipeline updates when Bristol-Myers (BMY) reports third-quarter 2020 results.

What's in the Cards for Regeneron's (REGN) Q3 Earnings?

by Zacks Equity Research

Investors will focus on the performance of Eylea and Dupixent along with other pipeline updates when Regeneron (REGN) reports third-quarter 2020 results.

Incyte (INCY) to Post Q3 Earnings: Will Jakafi Drive Results?

by Zacks Equity Research

Investors will focus on regular top and bottom-line numbers along with pipeline updates, when Incyte (INCY) reports third-quarter 2020 results.

Geron (GERN) Expected to Beat Earnings Estimates: Should You Buy?

by Zacks Equity Research

Geron (GERN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Geron (GERN) Looks Good: Stock Adds 6.5% in Session

by Zacks Equity Research

Geron (GERN) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.

Will Geron (GERN) Report Negative Q2 Earnings? What You Should Know

by Zacks Equity Research

Geron (GERN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Geron Sees Hammer Chart Pattern: Time to Buy?

by Zacks Equity Research

Geron has been struggling lately, but the selling pressure may be coming to an end soon

Geron Sees Hammer Chart Pattern: Time to Buy?

by Zacks Equity Research

Geron has been struggling lately, but the selling pressure may be coming to an end soon.

Is Geron (GERN) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Is (GERN) Outperforming Other Medical Stocks This Year?

Zealand Announces Dosing Initiation in Type 2 Diabetes Study

by Zacks Equity Research

Zealand's (ZEAL) partner, Boehringer Ingelheim, is developing BI 456906, a long-acting GLP-1/glucagon dual agonist, as a treatment for obesity and type 2 diabetes.

Geron's Shares March Higher, Can It Continue?

by Zacks Equity Research

As of late, it has definitely been a great time to be an investor in Geron.

Is Geron (GERN) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Is (GERN) Outperforming Other Medical Stocks This Year?

Dynavax's Partner Doses First Patient in Coronavirus Study

by Zacks Equity Research

Dynavax's (DVAX) China-based partner initiates dosing in a phase I study evaluating a COVID-19 vaccine using the company's proprietary CpG 1018 adjuvant. Preliminary data are expected in August.

Implied Volatility Surging for Geron Corporation (GERN) Stock Options

by Zacks Equity Research

Investors need to pay close attention to Geron Corporation (GERN) stock based on the movements in the options market lately.

Moving Average Crossover Alert: Geron

by Zacks Equity Research

Geron Corporation (GERN) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.

Dynavax Closes Enrollment in Renal Disease Study on Heplisav-B

by Zacks Equity Research

Dynavax (DVAX) is developing its hepatitis B vaccine, Heplisav-B, in patients with end-stage renal disease undergoing hemodialysis in a phase I study.